Nathan Weinstein
Stock Analyst at Aegis Capital
(0.26)
# 4,353
Out of 5,072 analysts
61
Total ratings
13.33%
Success rate
-26.26%
Average return
Main Sectors:
Stocks Rated by Nathan Weinstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EVGN Evogene | Maintains: Buy | $100 → $80 | $1.09 | +7,239.45% | 2 | Sep 12, 2022 | |
| DRIO DarioHealth | Maintains: Buy | $400 → $300 | $12.32 | +2,335.06% | 6 | Aug 18, 2022 | |
| VNRX VolitionRx | Maintains: Buy | $9 → $6 | $0.32 | +1,765.09% | 5 | Aug 15, 2022 | |
| IMUX Immunic | Maintains: Buy | $40 → $35 | $0.71 | +4,816.42% | 2 | Aug 8, 2022 | |
| STXS Stereotaxis | Initiates: Buy | $6 | $2.46 | +143.90% | 1 | Jul 12, 2022 | |
| ORMP Oramed Pharmaceuticals | Maintains: Buy | $35 → $30 | $2.85 | +952.63% | 5 | May 16, 2022 | |
| TRVI Trevi Therapeutics | Initiates: Buy | $10 | $13.19 | -24.18% | 1 | Mar 29, 2022 | |
| MDWD MediWound | Maintains: Buy | $63 → $49 | $17.92 | +173.44% | 4 | Mar 21, 2022 | |
| ENVB Enveric Biosciences | Downgrades: Hold | $63,000 → $1,800 | $5.87 | +30,590.54% | 2 | Mar 8, 2022 | |
| CING Cingulate | Initiates: Buy | $2,160 | $3.73 | +57,808.85% | 1 | Jan 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $120 | $2.60 | +4,515.38% | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $10 | $1.09 | +821.66% | 2 | Nov 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $160 | $219.88 | -27.23% | 2 | Sep 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $56 | $32.13 | +74.29% | 2 | Sep 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $27 | $3.89 | +594.09% | 3 | Aug 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $35 | $0.70 | +4,889.31% | 4 | Jun 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $2.38 | +404.20% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $8.73 | +759.11% | 1 | Jan 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $104 → $88 | $2.33 | +3,676.82% | 3 | Oct 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $180 | $4.90 | +3,573.47% | 1 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $195 → $135 | $4.70 | +2,772.34% | 3 | Aug 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $4.84 | +189.26% | 1 | Jul 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $220 | $16.01 | +1,274.14% | 7 | May 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8.5 | $4.58 | +85.59% | 1 | Mar 23, 2020 |
Evogene
Sep 12, 2022
Maintains: Buy
Price Target: $100 → $80
Current: $1.09
Upside: +7,239.45%
DarioHealth
Aug 18, 2022
Maintains: Buy
Price Target: $400 → $300
Current: $12.32
Upside: +2,335.06%
VolitionRx
Aug 15, 2022
Maintains: Buy
Price Target: $9 → $6
Current: $0.32
Upside: +1,765.09%
Immunic
Aug 8, 2022
Maintains: Buy
Price Target: $40 → $35
Current: $0.71
Upside: +4,816.42%
Stereotaxis
Jul 12, 2022
Initiates: Buy
Price Target: $6
Current: $2.46
Upside: +143.90%
Oramed Pharmaceuticals
May 16, 2022
Maintains: Buy
Price Target: $35 → $30
Current: $2.85
Upside: +952.63%
Trevi Therapeutics
Mar 29, 2022
Initiates: Buy
Price Target: $10
Current: $13.19
Upside: -24.18%
MediWound
Mar 21, 2022
Maintains: Buy
Price Target: $63 → $49
Current: $17.92
Upside: +173.44%
Enveric Biosciences
Mar 8, 2022
Downgrades: Hold
Price Target: $63,000 → $1,800
Current: $5.87
Upside: +30,590.54%
Cingulate
Jan 11, 2022
Initiates: Buy
Price Target: $2,160
Current: $3.73
Upside: +57,808.85%
Dec 7, 2021
Initiates: Buy
Price Target: $120
Current: $2.60
Upside: +4,515.38%
Nov 1, 2021
Maintains: Buy
Price Target: $9 → $10
Current: $1.09
Upside: +821.66%
Sep 22, 2021
Maintains: Buy
Price Target: $180 → $160
Current: $219.88
Upside: -27.23%
Sep 9, 2021
Maintains: Buy
Price Target: $60 → $56
Current: $32.13
Upside: +74.29%
Aug 17, 2021
Maintains: Buy
Price Target: $26 → $27
Current: $3.89
Upside: +594.09%
Jun 7, 2021
Maintains: Buy
Price Target: $40 → $35
Current: $0.70
Upside: +4,889.31%
Mar 22, 2021
Initiates: Buy
Price Target: $12
Current: $2.38
Upside: +404.20%
Jan 26, 2021
Initiates: Buy
Price Target: $75
Current: $8.73
Upside: +759.11%
Oct 19, 2020
Maintains: Buy
Price Target: $104 → $88
Current: $2.33
Upside: +3,676.82%
Oct 8, 2020
Initiates: Buy
Price Target: $180
Current: $4.90
Upside: +3,573.47%
Aug 3, 2020
Maintains: Buy
Price Target: $195 → $135
Current: $4.70
Upside: +2,772.34%
Jul 13, 2020
Initiates: Buy
Price Target: $14
Current: $4.84
Upside: +189.26%
May 4, 2020
Maintains: Buy
Price Target: $180 → $220
Current: $16.01
Upside: +1,274.14%
Mar 23, 2020
Initiates: Buy
Price Target: $8.5
Current: $4.58
Upside: +85.59%